Navigation Links
Ebola Treatment Shows Promise

Researchers publishing in the most recent issue of The Lancet believe they’re on the track to a possible treatment for the deadly Ebola virus.//

In a study conducted in rhesus monkeys, researchers found injections of a factor known to inhibit blood coagulation called rNAPc2 led to increased survival rates.

The Ebola virus kills its victims by causing severe hemorrhagic fever. This leads to excessive coagulation of the blood and, ultimately, organ failure. In outbreaks in Zaire, about 80 percent of people who contracted the virus died. The death rate in monkey models of the disease has been nearly 100 percent. These researchers wondered if the disease could be stopped by using rNAPc2 to inhibit the blood coagulation pathway.

Researchers from the United States Army Medical Research Institute of Infectious Diseases tested the treatment in nine monkeys who were intentionally infected with the virus. Three additional monkeys were infected with the virus but received no treatment and served as controls. Results show the treatment prolonged survival time. What’s more, 33 percent of the treated monkeys actually survived the disease and regained their health. Just one of the monkeys in the control group survived until the end of the study, and that monkey subsequently died.

The authors write, “Our results have great clinical implications, since our treatment approach of Ebola hemorrhagic fever targets the disease process rather than replication of the infectious agent.” Noting rNAPc2 has a good safety profile in humans, they believe it might also have a role to play in other viral hemorrhagic fevers. “The clinical efficacy of this treatment modality now needs to be proven,” they conclude.

'"/>




Page: 1

Related medicine news :

1. Ebola Virus - Outbreak Claims More Lives In Uganda.
2. Experimental treatment for Ebola Virus Shows promising results in mice
3. Ebola-like virus is on the way to cause epidemic in Angola
4. Fruit Bats Act As Carriers of Ebola Virus
5. Antisense gene specific therapy for Ebola virus
6. Ebola-Outbreak Kills 5000 Gorillas
7. Research on Vaccine Against Ebola Virus
8. Advances in Treatment of Cataracts
9. Recommendations for Treatment of Blood Pressue
10. Treatment for Menieres disease
11. Treatment for pre-menstrual syndrome is ineffective
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/13/2017)... Las Vegas, Nevada (PRWEB) , ... October 13, 2017 , ... ... of 7® Hemp CBD Oil utilizing Purzorb™ technology. Applying the Purzorb™process to full spectrum ... CBD dose required and providing a CBD form that can be easily incorporated into ...
(Date:10/13/2017)... ... October 13, 2017 , ... The Visiting Nurse Association (VNA) of Somerset Hills ... specialty vendors and unique items from across the nation, this holiday-themed event will raise ... offered by the VNA. The boutique will be open Saturday, November 4 (10:00 ...
(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, a leader in agile ... a contract by the Center for Medicare and Medicaid Services (CMS). The Enterprise ... use of Agile methodologies in a consistent and high value manner across CMS ...
(Date:10/12/2017)... Orleans, LA (PRWEB) , ... October 12, 2017 , ... ... centers in the U.S., announced today its plans to open a flagship location in ... will occupy the former Rooms To Go store next to Office Depot in the ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... that we intend to develop to enable prevention of a major side effect ... hearing loss, especially in pediatric patients. For cisplatin, hearing loss is FDA listed ...
Breaking Medicine News(10 mins):
(Date:9/27/2017)... CAESAREA, Israel and NEW YORK , Sept. ... company with mobile health and big data solutions, today announced that its ... today. Please check your local TV listings for when The Dr. Oz ... ... ninth season this month. ...
(Date:9/23/2017)... Sept. 22, 2017 Janssen Biotech, Inc. (Janssen) ... letter from the U.S. Food and Drug Administration (FDA) ... sirukumab for the treatment of moderately to severely active ... clinical data are needed to further evaluate the safety ... active RA. ...
(Date:9/19/2017)... HistoSonics, Inc., a venture-backed medical device company developing a non-invasive, robotically assisted, platform therapy that ... developments today:   ... ... Tom Tefft ... Veteran medical device executive Josh Stopek , PhD, who has led R&D and ...
Breaking Medicine Technology: